Abbott Laboratories news

   Watch this stock
Showing stories 1 - 10 of about 125   

Articles published

ABT 42.12 -0.26 (-0.63%)
price chart
Abbott Laboratories Tops Earnings Estimates
Abbott Laboratories (NYSE:ABT) released the earnings results from its third quarter before opening bell this morning, posting adjusted earnings of 62 cents per share, a 12.7% growth rate, on $5.1 billion in revenue.
Abbott Laboratories Sales Rise 5.8%  Wall Street Journal
Abbott Laboratories sales up 5.8%  MarketWatch
Related articles »  
Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals
ABBOTT PARK, Ill., Sept. 26, 2014 - Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets.
Company Update: Abbott Laboratories (NYSE:ABT) - Abbott Completes ...  Jutia Group
Abbott Labs Acquires Control Of CFR Pharma - Quick Facts  RTT News
Related articles »  
Will Abbott Labs (ABT) Miss on Earnings This Quarter?
Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie (ABBV - Analyst Report) in Jan 2013.
Abbott Expected To Report Upbeat Q3 Results
Abbott Laboratories (ABT) is scheduled to release third quarter (3Q) results for fiscal year 2014 (FY14) before market opens on October 22.
Abbott Laboratories (ABT) Weak In Early Morning Trading
Abbott Laboratories manufactures and sells health care products worldwide. The stock currently has a dividend yield of 2%. ABT has a PE ratio of 31.7.
National medical device company to close Houston-area facility  Houston Business Journal
RBC Capital Raises Abbott Laboratories Price Target to $48.00 (ABT)  sleekmoney
Related articles »  
AbbVie And Abbott Get Favorable Verdict In Racketeering Lawsuit
A federal court dismissed a racketeering lawsuit yesterday against AbbVie Inc. (ABBV) and Abbott Laboratories (ABT), which accused the companies of being involved in illegal co-pay programs for the two drugs, Humira and AndroGel.
Abbott Laboratories (ABT) Scheduled to Post Earnings on Wednesday
Abbott Laboratories logo Abbott Laboratories (NYSE:ABT) is set to release its Q314 earnings data on Wednesday, October 22nd.
Related articles »  
Abbott Laboratories Q3 14 Earnings Conference Call At 9:00 AM ET
( - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on October 22, 2014, to discuss its Q3 14 earnings result.
Related articles »  
abbott laboratories
Specifically, the agency charged several drug makers -- including AbbVie, Abbott Laboratories, which spun off AbbVie, and Teva Pharmaceuticals -- for striking deals that delayed the availability of the widely promoted AndroGel testosterone replacement ...
Related articles »  
Jefferies Has 5 Stocks to Buy With Big Catalysts This Week
Abbott Laboratories (NYSE: ABT) reports earnings on Wednesday and is Jefferies number two ranked stock pick globally. Because a product recall last year hammered earnings, the Jefferies analysts see very easy comparisons for the company this quarter.
Related articles »